Orthocell (ASX:OCC) said its revenue for the quarter ended Sept. 30 came in at $3 million, its highest result to date and the sixth consecutive quarter of record revenue, according to a Thursday Australian bourse filing.

Its revenue for the same period in the previous year was $2 million.

The firm is targeting inclusion in the ASX 300 index as part of its three-year vision. It seeks to advance its product pipeline with collagen scaffold applications in musculoskeletal repair, build a nerve repair portfolio, and validate advancements in cell therapy technology.

It is also focused on the launch of its Remplir nerve repair product in the US and Canada, as well as the onboarding of "strategic" countries in Asia.